Incidence of Choroidal Neovascularization in the Fellow Eye in the Comparison of Age-Related Macular Degeneration Treatments Trials – Corrected Proof

Objective: To assess the influence of drug; dosing regimen; and traditional, nontraditional, and genetic risk factors on the incidence of choroidal neovascularization (CNV) in the fellow eye of patients treated for CNV with ranibizumab or bevacizumab.Design: Cohort study of patients enrolled in a multicenter, randomized clinical trial.Participants: Patients with no CNV in the fellow eye at the time of enrollment in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).Methods: Eligibility criteria for the clinical trial required that study eyes have evidence on fluorescein angiography and optical coherence tomography of CNV secondary to age-related macular degeneration (AMD) and visual acuity (Read more...)

Full Story →